CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
SRM003 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01806545
NCT01806545Phase 2Completed

A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access

Shire·interventional·Posted Mar 7, 2013·Updated Jun 8, 2021

In Brief

A Phase 2 clinical trial evaluating SRM003 and Participating Site's standard practice for Arteriovenous Fistula. Completed, enrolled 64 participants across 47 sites.

Detailed Summary

A study to evaluate the efficacy of SRM003 treatment versus participating sites' standard practice treatment in improving the rate of AVF maturation and use in subjects with end-stage renal disease undergoing surgery for creation of an AVF to facilitate hemodialysis access. It is hypothesized that when placed outside the blood vessel, the seeded SRM003 gelatin matrix containing endothelial cells can provide a continuous supply of multiple growth regulatory compounds to the underlying cells within the blood vessel, while being protected from the effects of blood flow in the vessel(s) or complications resulting from being in direct contact with the point of injury.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 7, 2013
Enrollment StartMar 26, 2013
Primary CompletionOct 27, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.3 years ago

Interventions

SRM003biological

One time implant (2 SRM003 pieces) on surgery day.

Participating Site's standard practiceother

Subjects will receive sites' standard practice treatment during the surgical procedure.